Navigation Links
Quotient Clinical and Bend Research Announce Collaboration to Accelerate Advancement of New Medicines
Date:11/10/2010

BEND, Ore. and NOTTINGHAM, England, Nov. 10, 2010 /PRNewswire/ -- Bend Research Inc. (www.bendres.com), a leading independent drug-formulation development and manufacturing company, and Quotient Clinical, a business unit of Quotient Bioresearch ("Quotient," www.quotientbioresearch.com), a leading developer of compounds through clinical trials, announced today a nonexclusive collaboration that can speed the advance of compounds to clinical trials and expand options for drug delivery.

The collaboration combines Bend Research's advanced drug formulation capabilities and Quotient's clinical-trial design service, RapidFACT™. The result is a clinical-trial program that will allow clients to screen and select optimized formulations rapidly during human testing. For example, optimum bioavailability-enhancing formulations relying on amorphous and nanocrystalline dispersions can be quickly identified using the highly flexible clinical trial designs pioneered by Quotient.

"This collaboration takes advantage of the proven strengths of our two companies," said Bend Research President and CEO Rod Ray. "The versatility of designing and implementing clinical trials using RapidFACT provides our clients with a game-changing advantage in advancing their compounds."

Mark Egerton, Managing Director of Quotient Clinical, agreed on the value of the collaboration. "Poorly soluble compounds are becoming ever more prevalent in the industry's pipeline, and we have many customers who require formulation help to advance such problematic compounds. Access to Bend Research's leading formulation expertise through this collaboration will provide our customers with reliable, rapid and efficient drug formulation platforms," he said.

Accessing Bend Research formulations at Quotient's clinical research site means that clinical studies can happen much more quickly than was previously possible. One client has already taken advantage of the collaboration with the successful transfer of a Bend Research formulation to Quotient's cGMP manufacturing facility in Nottingham, U.K.

Ray and Egerton will be available for discussions at the upcoming American Association of Pharmaceutical Scientists (AAPS) in November in New Orleans.

About Quotient Clinical

Quotient Clinical is a leading provider of early clinical development services. With more than 20 years experience, Quotient Clinical offers a uniquely streamlined process, reducing the time from First in Human to Proof of Concept and integrating flexible drug product manufacture into clinical trials. Quotient Clinical's principal focus is to provide a unique and comprehensive range of high-quality early-development services to pharmaceutical and biotechnology customers worldwide.

RapidFACT (Rapid Formulation development And Clinical Testing) represents a new paradigm for drug product optimization. It exploits Quotient's integrated formulation development, drug product manufacture, and clinical-testing platform. Candidate formulations can be rapidly screened, selected, and validated on the basis of their performance in man – dramatically improving the chances of identifying a drug product that can achieve the target product profile.

Quotient Bioresearch is a leading provider of early-stage and specialist drug development services to pharmaceutical, biotechnology, and medical-device clients worldwide. The company offers a wide range of drug development services through its three key focus areas: Chemistry and Metabolism, Bioanalytical Sciences and Clinical. Quotient has grown rapidly in the past 3 years, through a combination of acquisition-led and organic growth.

For more information about Quotient and its capabilities, please contact Sarah Evans at The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom (telephone: +44 1477 539 539; fax: +44 1477 539 540; e-mail: quotient@scottpr.com).

About Bend Research Inc.

For more than 30 years, Bend Research has worked with clients to create value by advancing new medicines and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies. The firm's innovative drug-delivery solutions grow from a solid base of scientific and engineering fundamental understanding.

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through commercialization.

Bend Research currently works with more than 50 pharmaceutical and biotechnology clients worldwide. The company has more than 180 employees based in four state-of-the-art facilities in Bend, Oregon, USA. For more information about Bend Research and its formulation and manufacturing capabilities, please contact Dana Settell via email at Dana.Settell@bendres.com or phone at 541-382-4100.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Results of Two New Clinical Studies Show Promise of Emerging Mobile Health Technology to Combat Obesity Epidemic
2. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
3. AAOS Clinical Guideline for Treating Spinal Compression Fractures Presents More Questions Than Answers for Medical Community
4. US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment
5. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
6. EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows
7. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
8. PAREXEL Expert to Lead Track on Global Clinical Outsourcing at Partnerships in Clinical Trials Europe Conference
9. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
10. Sanofi Pasteurs Dengue Vaccine in Final Stage of Clinical Development
11. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
(Date:4/28/2016)... , April 28, 2016 Research ... "Global Plastic Surgery Products Market 2016-2020" report to ... ) , The global plastic surgery products ... 9.47% during the period 2016-2020. , ,The growing adoption ... to the growth of the market. Lasers are used ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
Breaking Medicine Technology:
(Date:4/30/2016)... MA (PRWEB) , ... April 30, 2016 , ... ... organization, today announced RANKED Health , a program to critically evaluate and ... major goal of the program is to provide independent, unbiased and accurate information ...
(Date:4/30/2016)... Rosa, CA (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but ... NCMA’s Dr. Parul T. Kohli . “Research is showing more and more that there ... risk of disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by environmental ... deal with these stressors is to adopt a more healthful diet, but too many ... Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and ...
(Date:4/29/2016)... ... 2016 , ... The White House announced efforts yesterday to ... about their loan terms and accounts, and more protections for borrowers. The announcement ... private loans, has reached $1.3 trillion, with 43 million Americans holding student loans ...
Breaking Medicine News(10 mins):